Fabrication and Evaluation of 2-Hydroxyethyl Methacrylate-co-Acrylic Acid Hydrogels for Sustained Nicorandil Delivery
Purpose: To fabricate and evaluate oral 2-hydroxyethyl methacrylate co-acrylic acid hydrogels as a drug delivery system for sustained release of nicorandil.
Methods: HEMA-co-AA hydrogels using different monomer concentrations were prepared by free radical polymerization. N, N-methylene bis acrylamide (MBA) was used as crosslinker and potassium persulphate (KPS) as initiator. Nicorandil (20 mg) loaded hydrogels were characterized by Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis and differential scanning calorimetry (DSC) and scanning electron microscopy (SEM) . Swelling ratio, equilibrium swelling (ES), gel content (gc), porosity measurement (P) and in vitro drug release of the delivery system were evaluated.
Results: Swelling ratio and ES decreased as AA concentration (%) was reduced from 3.173 to 2.93 (pH 1.2) and 16.42 to 15.01 (pH 7.4) and 68.49 to 65.90 (pH 1.2) and 93.91 to 93.34 (pH 7.4), respectively, while HEMA and MBA showed opposite effects. Gel content (%) and porosity (%) ranged from 83.76 to 88.0, respectively from F1 to F9. With increase monomer content (AA), drug release increased from 85.99 to 89.38 %. However, when the concentrations of HEMA and MBA were raised, drug release decreased.
Conclusion: HEMA-co-AA hydrogels are potential pH-sensitive and sustained-release system for nicorandil.
Keywords: Hydrogel, 2-Hydroxyethyl Methacrylate-co-acrylic Acid, Sustained Drug Release, Monomer, Nicorandil, Swelling Ratio, Porosity
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.